{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:14:11Z","timestamp":1772003651868,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011033","name":"Thermo Fisher Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011112","name":"UCB US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01646-1","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:22:05Z","timestamp":1768843325000},"page":"1331-1345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Features Associated with Therapy Switch Among PPD CorEvitas Psoriasis Registry Patients"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4404-6065","authenticated-orcid":false,"given":"Andrea M.","family":"Austin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott C.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha C.","family":"Trujillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Eliot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra I.","family":"Main","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J.","family":"Litman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omeed","family":"Nabavian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"10281","key":"1646_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301\u201315.","journal-title":"Lancet"},{"key":"1646_CR2","unstructured":"Global report on psoriasis. World Health Organization. Updated October 26, 2016. https:\/\/www.who.int\/publications\/i\/item\/9789241565189. Accessed 19 Feb 2025."},{"issue":"6","key":"1646_CR3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.","journal-title":"Int J Mol Sci"},{"key":"1646_CR4","doi-asserted-by":"publisher","first-page":"102292","DOI":"10.1016\/j.coph.2022.102292","volume":"67","author":"CP Lin","year":"2022","unstructured":"Lin CP, Merola JF, Wallace EB. Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis. Curr Opin Pharmacol. 2022;67:102292.","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"1646_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","volume":"76","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1646_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/dth.12267","volume":"28","author":"F Kerdel","year":"2015","unstructured":"Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015;28(6):390\u2013403.","journal-title":"Dermatol Ther"},{"issue":"9","key":"1646_CR7","first-page":"504","volume":"9","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504\u201313.","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"1646_CR8","doi-asserted-by":"publisher","first-page":"217608","DOI":"10.1080\/09546634.2023.2176708","volume":"34","author":"S Thai","year":"2023","unstructured":"Thai S, Zhuo J, Zhong Y, et al. Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies. J Dermatol Treat. 2023;34(1):217608.","journal-title":"J Dermatol Treat"},{"key":"1646_CR9","unstructured":"Birt J, Grabner M, Isenberg K, et al. Inadequate response among psoriatic arthritis patients prescribed advanced therapy in a real-world US commercially insured population [abstract]. Arthritis Rheumatol. 2020;72(suppl 10):0898."},{"issue":"4","key":"1646_CR10","first-page":"479","volume":"25","author":"SR Feldman","year":"2019","unstructured":"Feldman SR, Tian H, Wang X, Germino R. Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large US claims database. J Manag Care Spec Pharm. 2019;25(4):479\u201388.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3 suppl 1","key":"1646_CR11","doi-asserted-by":"publisher","first-page":"AB81","DOI":"10.1016\/j.jaad.2023.07.329","volume":"89","author":"JJ Wu","year":"2023","unstructured":"Wu JJ, Patel M, Li C, Mandava MR, Armstrong AW. Real-world switch rates of biologics and associated costs in patients with psoriasis [abstract]. J Am Acad Dermatol. 2023;89(3 suppl 1):AB81.","journal-title":"J Am Acad Dermatol"},{"issue":"5 suppl 1","key":"1646_CR12","first-page":"AB191","volume":"70","author":"U Mallya","year":"2014","unstructured":"Mallya U, Qureschi A, Lahoz R. The economic burden of switching biologics in psoriasis: a real-world analysis in the US population [abstract]. J Am Acad Dermatol. 2014;70(5 suppl 1):AB191.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1646_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","volume":"78","author":"B Strober","year":"2018","unstructured":"Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323\u201332.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1646_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12874-022-01774-8","volume":"22","author":"AM Austin","year":"2022","unstructured":"Austin AM, Ramkumar N, Gladders B, et al. Using a cohort study of diabetes and peripheral artery disease to compare logistic regression and machine learning via random forest modeling. BMC Med Res Methodol. 2022;22(1):300.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"1646_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L. Random forests. Mach Learn. 2001;45(1):5\u201332.","journal-title":"Mach Learn"},{"issue":"3","key":"1646_CR16","first-page":"9","volume":"1","author":"K Kirasich","year":"2018","unstructured":"Kirasich K, Smith T, Sadler B. Random forest vs logistic regression: binary classification for heterogeneous datasets. SMU Data Sci Rev. 2018;1(3):9.","journal-title":"SMU Data Sci Rev"},{"key":"1646_CR17","first-page":"1063","volume":"13","author":"G Biau","year":"2012","unstructured":"Biau G. Analysis of a random forests model. J Mach Learn Res. 2012;13:1063\u201395.","journal-title":"J Mach Learn Res"},{"issue":"1","key":"1646_CR18","first-page":"665","volume":"32","author":"M Denil","year":"2014","unstructured":"Denil M, Matheson D, de Freitas N. Narrowing the gap: random forests in theory and in practice. PMLR. 2014;32(1):665\u201373.","journal-title":"PMLR"},{"key":"1646_CR19","doi-asserted-by":"publisher","first-page":"105241","DOI":"10.1016\/j.ijmedinf.2023.105241","volume":"180","author":"A Iancu","year":"2023","unstructured":"Iancu A, Leb I, Prokosch HU, R\u00f6dle W. Machine learning in medication prescription: a systematic review. Int J Med Inform. 2023;180:105241.","journal-title":"Int J Med Inform"},{"issue":"5","key":"1646_CR20","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s10439-024-03459-3","volume":"52","author":"VA Binson","year":"2024","unstructured":"Binson VA, Thomas S, Subramoniam M, Arun J, Naveen S, Madhu S. A review of machine learning algorithms for biomedical applications. Ann Biomed Eng. 2024;52(5):1159\u201383.","journal-title":"Ann Biomed Eng"},{"issue":"4","key":"1646_CR21","first-page":"e57728","volume":"16","author":"M Elhaddad","year":"2024","unstructured":"Elhaddad M, Hamam S. AI-driven clinical decision support systems: an ongoing pursuit of potential. Cureus. 2024;16(4):e57728.","journal-title":"Cureus"},{"key":"1646_CR22","unstructured":"National Psoriasis Foundation. FY25-29 Strategic Plan. https:\/\/npf-website.cdn.prismic.io\/npf-website\/ZoKt1R5LeNNTwrl8_StrategicPlanFINAL.pdf. Accessed 14 Mar 2025."},{"issue":"4","key":"1646_CR23","first-page":"396","volume":"22","author":"SA Foster","year":"2016","unstructured":"Foster SA, Zhu B, Guo J, et al. Patient characteristics, health care resource utilization, and costs associated with treatment-regimen failure with biologics in the treatment of psoriasis. J Manag Care Spec Pharm. 2016;22(4):396\u2013405.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"1646_CR24","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s13555-021-00627-4","volume":"11","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among biologic-experienced patients with psoriasis treated with ixekizumab or secukinumab over 18\u00a0months. Dermatol Ther Heidelb. 2021;11(6):2133\u201345.","journal-title":"Dermatol Ther Heidelb"},{"issue":"1","key":"1646_CR25","doi-asserted-by":"publisher","first-page":"2200870","DOI":"10.1080\/09546634.2023.2200870","volume":"34","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Patel M, Li C, Garg V, Manava MR, Wu JJ. Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. J Dermatolog Treat. 2023;34(1):2200870.","journal-title":"J Dermatolog Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01646-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:41:24Z","timestamp":1772001684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01646-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01646-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrea M. Austin and Heather J. Litman are employees and shareholders of Thermo Fisher Scientific. Scott C. Henderson and Melissa Eliot are employees of Thermo Fisher Scientific. Natasha C. Trujillo, Robert Low\u00a0and Omeed Nabavian are employees and shareholders of UCB. At the time of the study, Sandra I. Main was an employee of Thermo Fisher Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice (GPP). All participating investigators were required to obtain full board approval for conducting non-interventional research involving human subjects with a limited dataset. Sponsor approval and continuing review was obtained through a central institutional review board (IRB, Advarra, Protocol Number Pro00051221). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to Thermo Fisher Scientific prior to the initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization prior to participating.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}